Grace & White Inc. NY Purchases 1,871 Shares of SWK Holdings Co. (NASDAQ:SWKH)

Grace & White Inc. NY raised its holdings in shares of SWK Holdings Co. (NASDAQ:SWKH) by 11.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,721 shares of the company’s stock after acquiring an additional 1,871 shares during the period. Grace & White Inc. NY owned about 0.15% of SWK worth $297,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Victory Capital Management Inc. purchased a new stake in shares of SWK in the 3rd quarter valued at $589,000. JPMorgan Chase & Co. lifted its stake in SWK by 224.4% in the third quarter. JPMorgan Chase & Co. now owns 6,108 shares of the company’s stock worth $106,000 after purchasing an additional 4,225 shares during the last quarter. Barclays PLC boosted its position in SWK by 185.0% during the third quarter. Barclays PLC now owns 4,461 shares of the company’s stock valued at $77,000 after buying an additional 2,896 shares during the period. Finally, SkyView Investment Advisors LLC grew its stake in shares of SWK by 2.1% during the third quarter. SkyView Investment Advisors LLC now owns 31,815 shares of the company’s stock valued at $550,000 after buying an additional 650 shares during the last quarter. 99.27% of the stock is owned by hedge funds and other institutional investors.

SWK Stock Down 1.0 %

SWKH opened at $16.50 on Thursday. The company has a market cap of $201.80 million, a P/E ratio of 17.74 and a beta of 0.37. SWK Holdings Co. has a 12 month low of $15.14 and a 12 month high of $18.49. The business’s 50-day moving average price is $16.31 and its 200-day moving average price is $16.62. The company has a current ratio of 5.06, a quick ratio of 5.06 and a debt-to-equity ratio of 0.11.

About SWK

SWK Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors.